搜尋結果
2024年3月21日 · On Thursday, Goldman Sachs (NYSE: GS ) adjusted its outlook on shares of BioNTech SE (NASDAQ: BNTX ), reducing the price target to $91 from the previous $100, while retaining a Neutral rating on the stock. The move follows BioNTech's fourth-quarter earnings report, which revealed sales of its Comirnaty COVID-19 vaccine did not meet expectations ...
2024年4月7日 · Biontech ile ilgili tüm haberler için doğru yerdesiniz. Güncel, son dakika Biontech haberleri ve en sıcak haber akışını bu sayfa üzerinden takip edebilirsiniz.
2024年3月25日 · BioNTech reduces drug development spend as COVID vaccine sales plunge. August 7, 2023. 1 to 20 of 87. The latest international BioNTech AG news and views from Reuters - one of the world's largest ...
2024年3月26日 · BioNTech SE's chief operating officer issued a U.S. Securities and Exchange Commission (SEC) filing on March 22, 2024, confirming that it previously disclosed that the Company was in discussions with the National Institutes of Health ("NIH") concerning royalties and other amounts allegedly owed on sales of the Company's COVID-19 vaccine since commercialization.
2024年4月10日 · BioNTech drew a crowd for its presentation, no doubt due to the fame garnered from the German company's COVID-19 vaccine. Kopetz said the rise of mRNA is one of the reasons cancer vaccines have ...
2024年3月26日 · Pictured: BioNTech's signage outside its headquarters in Germany/iStock, U.J. Alexander The National Institutes of Health has slapped BioNTech with a notice of default over alleged royalty payments the biotech owes the agency related to sales of its Pfizer-partnered COVID-19 vaccine Comirnaty, according to the company’s SEC filing.
2024年4月7日 · MAINZ, Germany, April 7, 2024 - BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy (“iNeST”) candidate autogene cevumeran (also known as BNT122, RO7198457) in patients with resected pancreatic ...
